Minocycline intravenous - The Medicines Company

Drug Profile

Minocycline intravenous - The Medicines Company

Alternative Names: Minocin; Minocin IV; Minocin® for Injection; Minocycline hydrochloride - The Medicines Company; RPX 602

Latest Information Update: 07 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rempex Pharmaceuticals
  • Developer Rempex Pharmaceuticals; The Medicines Company
  • Class Amides; Antibacterials; Dimethylamines; Neuroprotectants; Small molecules; Tetracyclines
  • Mechanism of Action Glial cell inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gram-negative infections; Gram-positive infections

Most Recent Events

  • 01 May 2017 Phase-I clinical trials in Gram-negative and Gram-positive infections (In volunteers) in Germany (IV) (NCT02808052)
  • 20 Apr 2017 Phase-I clinical trials in Gram-negative and Gram-positive infections (In volunteers) in Netherlands (IV) (NCT02802631)
  • 17 Jun 2016 Rempex Pharmaceuticals and Universitätsklinikum Köln plan a phase I trial in Healthy volunteers in Germany (Injection) (NCT02808052)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top